[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-microvascular-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-microvascular-dysfunction":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,47,71,104,130,151,187,215,242,269,301,328,351,371,390,415,439,466],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100642956","coronary-thrombus-modification-to-prevent-microvascular-damage-in-patients-with-st-segment-elevation-myocardial-infarction-the-cormi-trial-100642956",false,"NCT07646977","CORonary Thrombus Modification to Prevent MIcrovascular Damage in Patients With ST-segment Elevation Myocardial Infarction (The CORMI Trial)","Inclusion Criteria:\n\n* ST-elevation at the J-junction in a minimum of two contiguous ECG leads with a minimum of ≥ 0.1 mV in all leads, except for V2 and V3 (which required ≥ 0.2 for men ≥ 40 years old, ≥ 0.25 in men \\\u003C 40 years old, or ≥ 0.15 mV for all women) or new left bundle branch\n* Admission to hospital within 12 hours of symptom debut\n* Angiographic signs of a culprit lesion planned to be treated with primary percutaneous coronary intervention\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years or inability to provide informed consent\n* Life expectancy of \\\u003C 12 months\n* Hemodynamically instability\n* Pregnancy or breastfeeding\n* Known asthma or severe chronic obstructive pulmonary disease\n* Expected inability to perform physiological measurements (due to severely tortuous arteries, ostial disease or very distal disease),\n* CMR contraindications (estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin, magnetic or mechanically activated implants, or any prior metal implants, severe claustrophobia)\n* Expected to or unavoidable to use thrombectomy","ALL","18 Years",{"count":18,"type":19},100,"ESTIMATED","INTERVENTIONAL",[22],"NA","The aim of this study is to evaluate the effects of coronary thrombus modification on preventing the microvascular damage associated with primary percutaneous coronary intervention (PCI), and to limit the associated myocardial damage assessed by myocardial salvage index after 3 months. Furthermore, the project will evaluate coronary microvascular damage assessed invasively using both continuous and bolus thermodilution before and after stent implantation. In addition, the project will evaluate the diagnostic ability and associations of pre-stenting invasive physiological measurement to cardiac magnetic resonance imaging measurements.",[25,26,27],"ST Elevation Myocardial Infarction","Coronary Microvascular Dysfunction","Percutaneous Coronary Intervention",[29,30,31,32,33],"Microvascular damage","Continuous thermodilution","Bolus thermodilution","Myocardial damage","Cardiac MRI","NOT_YET_RECRUITING","2026-06-19",{"date":37,"type":38},"2026-06-24","ACTUAL",{"date":40,"type":19},"2026-06",{"date":42,"type":19},"2034-01",{"name":44,"class":45},"Odense University Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":20,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100592276","self-expanding-coronary-sinus-reducer-for-treatment-of-symptomatic-coronary-microvascular-dysfunction-cmd-serra-i-study-100592276","NCT06991322","Self-Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD) (SERRA-I Study)","Inclusion Criteria:\n\n1. Older than 18 years of age.\n2. Left ventricular ejection fraction (LVEF) is greater than or equal to 25% within the 12 months before the index procedure.\n3. Greater than or equal to 30 days of persistent symptomatic coronary microvascular dysfunction (angina pectoris, or equivalent symptoms) (classified as CCS Grade II-IV angina, or NYHA Class 2 or 3 equivalent non-anginal functional impairment) despite optimal medical therapy as determined by Investigator and confirmed by the Central Screening Committee.\n4. CFR\\\u003C2.5 measured with continuous thermodilution within 30 days of index procedure.\n5. Sustained angina (or equivalent symptoms) reported for at least 2 weeks leading up to the index procedure, as reported via the ORBITA-app.\n6. Willing and able to sign informed consent.\n7. Willing to comply with the specified follow-up evaluations.\n8. Mean right atrial pressure ≤15 mmHg.\n9. The CS anatomy is suitable for implantation at the Investigator's discretion.\n\nExclusion Criteria:\n\n1. Significant obstructive epicardial disease (greater than 50% diameter stenosis) that can be treated with PCI or CABG as determined by Investigator and confirmed by the Central Screening Committee.\n2. Recent (less than 30 days before index procedure) troponin or CKMB positive acute coronary syndrome (NSTEMI or STEMI) with evidence of ischemia.\n3. Extra-coronary contributory causes of angina - e.g., untreated hyperthyroidism, anemia (Hgb less than 9 g\u002FdL), uncontrolled hypertension (systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg despite medications), atrial fibrillation with a rapid ventricular response (consistently greater than 100 bpm despite medications) or other tachyarrhythmia, severe aortic stenosis, decompensated heart failure, hypertrophic cardiomyopathy with left ventricular outflow tract obstruction or asymmetric septal hypertrophy (concentric left ventricular hypertrophy is not an exclusion criterion).\n4. NYHA class IV or decompensated HF or hospitalization due to HF during the 90 days before the index procedure.\n5. Life-threatening rhythm disorders or any rhythm disorders that would require cardiac resynchronization therapy or lead placement in the coronary sinus.\n6. Severe chronic obstructive pulmonary disease (COPD) as indicated by a forced expiratory volume in one second (FEV1) of less than 1.0L or need for home daytime oxygen or regular oral steroids.\n7. Severe valvular heart disease (any valve).\n8. Moderate (TAPSE\\\u003C12) or severe RV dysfunction (TAPSE\\\u003C8) by echocardiography.\n9. A pacemaker electrode\u002Flead is present in the coronary sinus.\n10. Recent implantation of a new pacemaker or defibrillator leads with any electrode in the right atrium within 90 days of the index procedure.\n11. Chronic severe renal failure (estimated eGFR less than 30 mL\u002Fmin\u002F1.73m2 or equivalent) or subjects on chronic dialysis.\n12. Known allergy to titanium, nickel, platinum, tungsten or known inability to tolerate contrast medium.\n13. Any clinical condition that might interfere with the trial protocol or the subject's ability to be compliant with the trial protocol (e.g., active alcohol or illicit substance use, cognitive decline).\n14. Currently enrolled in another investigational device or drug trial that has not reached its primary endpoint or might clinically interfere with the current trial endpoints or procedures.\n15. Pregnant or planning pregnancy within the next 12 months (females of reproductive potential must have a negative pregnancy test within 7 days of the procedure).\n16. Part of a vulnerable population who, in the investigator's judgment, cannot give Informed Consent for reasons of incapacity, immaturity, adverse personal circumstances, or lack of autonomy.\n17. Inability to tolerate dual antiplatelet therapy for 6 months if not on a chronic oral anticoagulant, or inability to tolerate a P2Y12 inhibitor for at least 6 months if on a chronic oral anticoagulant.\n18. Comorbidities limiting life expectancy to less than one year.\n19. Currently hospitalized for definite or suspected COVID-19.",{"count":54,"type":19},30,[22],"VahatiCor's Coronary Sinus Reducer (A-FLUX) has been designed to improve angina or angina-like symptoms in patients with CMD. SERRA-I is an early feasibility study that evaluates the safety and clinical performance of the A-FLUX Reducer in this population.",[26,58],"Coronary Microvascular Disease","RECRUITING","2026-05-14",{"date":62,"type":38},"2026-05-15",{"date":64,"type":38},"2025-06-18",{"date":66,"type":19},"2027-04",{"name":68,"class":69},"VahatiCor, Inc.","INDUSTRY",3,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":15,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":82,"studyType":83,"phases":4,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":46},"100460207","coronary-microvascular-dysfunction-assessments-in-myocardial-infarction-with-non-obstructive-coronary-arteries-100460207","NCT05272618","Coronary Microvascular Dysfunction Assessments in Myocardial Infarction With Non-Obstructive Coronary Arteries","Clinical Relevance of Coronary Microvascular Dysfunction Assessments in Myocardial Infarction With Non-Obstructive Coronary Arteries","CMD-MINOCA","Inclusion Criteria:\n\n* Subject with age ≥19 years and acute myocardial infarction\n\n  * Rise and\u002For fall of cardiac troponin with one level \\>99 percentile plus ischemic signs\u002Fsymptoms\n\n    * Subject with non-obstructive coronary arteries\n  * \\\u003C50% diameter stenosis or\n  * fractional flow reserve (FFR) \\>0.80 ③ Subject without previous history of coronary artery disease\n\n    * Subject who performed invasive coronary angiography within 24 hours after presentation ⑤ Subject who eligible for invasive and non-invasive coronary physiologic assessment\n\nExclusion Criteria:\n\n* Subject with obstructive coronary arteries\n\n  * Subject with alternate diagnosis including sepsis, pulmonary embolism, myocarditis, Takotsubo syndrome, spontaneous coronary dissection, and other cardiomyopathies.\n\n    * Subject with cardiogenic shock or cardiac arrest ④ Subject who has non-cardiac co-morbid conditions with life expectancy \\\u003C1 year ⑤ Subject or lactating women ⑥ Subject unable to provide consent","19 Years",{"count":81,"type":19},150,"12 Months","OBSERVATIONAL","To compare clinical outcomes of myocardial infarction with non-obstructive coronary arteries (MINOCA) according to the coronary microvascular dysfunction (CMD), evaluated by optical coherence tomography (OCT), invasive and non-invasive coronary physiologic assessment.",[86,26,87],"Myocardial Infarction","Vasospasm, Coronary",[89,90,91,92,93,94],"MINOCA","Coronary physiology","Cardiac PET","CFR","IMR","OCT","2026-05-08",{"date":97,"type":38},"2026-05-12",{"date":99,"type":38},"2022-02-14",{"date":101,"type":19},"2030-12-31",{"name":103,"class":45},"Chonnam National University Hospital",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":114,"conditions":115,"keywords":119,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":46},"100503894","coronary-flow-during-rapid-heart-rates-100503894","NCT05841199","Coronary Flow During Rapid Heart Rates","Coronary Epicardial and Microcirculatory Determinants of Ventricular Tachycardia Tolerability","VT flow","Inclusion Criteria:\n\n* Able to give valid consent\n* Referred for coronary angiography or coronary angioplasty\n* Suitable for percutaneous physiological interrogation and PCI when clinically indicated\n\nExclusion Criteria:\n\n* Unable to give valid consent\n* Pregnant or breastfeeding women\n* Unstable coronary artery disease (acute coronary syndrome)\n* Severe multivessel coronary artery disease suitable for coronary artery bypass grafting\n* Severe heart valve disease\n* Severe (NYHA IV) heart failure",{"count":113,"type":19},70,"The goal of this observational study is to learn about the factors which determine how well ventricular tachycardia (VT) is tolerated. The main questions it aims to answer are:\n\n1. What impact does coronary artery disease have on the ability for a patient to tolerate VT?\n2. Does treatment of coronary artery disease with stents improve the tolerability of VT?\n\nParticipants who are undergoing a clinically indicated coronary angiogram or coronary angioplasty procedure will have measurements of blood pressure, coronary pressure and coronary flow made during pacing at a range of heart rates.",[116,117,118,26,58],"Ventricular Tachycardia","Coronary Artery Disease","Heart Failure",[116,117,118,26,58,27,120],"Implantable Cardioverter Defibrillator","2026-03-24",{"date":123,"type":38},"2026-03-27",{"date":125,"type":38},"2023-08-01",{"date":127,"type":19},"2026-06-02",{"name":129,"class":45},"Imperial College London",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":46},"100600133","a-study-of-cs-reducer-for-symptomatic-heart-failure-with-hfpef-and-cmd-100600133","NCT07093528","A Study Of CS Reducer For Symptomatic Heart Failure With HFpEF And CMD","CMR Substudy of Coronary Sinus Reducer for the Management of Symptomatic Heart Failure With a Preserved Ejection Fraction (HFpEF) Associated With Coronary Microvascular Dysfunction (CMD)","Inclusion Criteria:\n\n* Age ≥18\n* Enrollment in main CS-reducer HFPEF study IRB# 25-002292\n\nExclusion Criteria:\n\n* Metal implants that are not suitable for MRI\n* Inability or unwillingness of individual to give written informed consent.",{"count":138,"type":19},25,"To evaluate the effect of CS reducer implantation in patients with HFPEF and CMD on myocardial ischemia, measured by stress myocardial perfusion using cardiovascular magnetic resonance (CMR)",[141,26],"Heart Failure With Preserved Ejection Fraction","2026-02-24",{"date":144,"type":38},"2026-02-27",{"date":146,"type":38},"2025-10-16",{"date":148,"type":19},"2027-08",{"name":150,"class":45},"Mayo Clinic",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":159,"minAge":160,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":20,"phases":164,"briefSummary":166,"conditions":167,"keywords":170,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":46},"100580945","phase-2-improving-coronary-vascular-health-in-women-100580945","NCT06843902","Improving Coronary Vascular Health in Women","ImproviNg Coronary Vascular Health in Women With Risk Factors fOR Myocardial Infarction Type 2 (INFORM-2)","INFORM_2","Inclusion Criteria:\n\n* female sex-at-birth\n* self-report of HIV on stable antiretroviral therapy ≥180 days\n* age 45 -75 years\n* at least 1 of the following 3 conditions: i) type 2 diabetes mellitus ii) estimated glomerular filtration rate 30-60 ml\u002Fmin\u002F1.73 m2 iii) urine albumin to creatinine ratio \\>30 mg\u002Fg\n* coronary flow reserve \\\u003C2.5 or stress myocardial blood flow \\\u003C2.5 on screening cardiac positron emission tomography\u002Fcomputed tomography\n\nExclusion Criteria:\n\n* current SGLT2 inhibitor use\n* known allergy to SGLT2 inhibitor use\n* type 1 diabetes or ketoacidosis prone diabetes (diabetes with a history of ketoacidosis)\n* self-reported history of polycystic kidney disease\n* self-reported history of myocardial infarction, stroke, or coronary revascularization\n* stable or unstable angina\n* self-reported history of heart failure\n* hemoglobin A1c ≥8.5% at screen\n* uncontrolled hypertension at screen, defined as systolic blood pressure ≥180 mm Hg and\u002For diastolic blood pressure ≥110 mm Hg\n* estimated glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F1.73 m2\n* currently receiving hemodialysis or peritoneal dialysis\n* CD4 \\\u003C400 cell\u002Fmm3\n* current treatment with systemic (oral, IV, IM or intra-articular) steroids or anti-inflammatory\u002Fimmune suppressant therapies (excluding topical therapies, UV therapy, ASA-derivatives, or NSAIDs) for any indication, including kidney disease\n* pregnancy or breastfeeding\n* known allergy to 13N Ammonia\u002F82Rubidium or to Regadenoson\u002FAdenosine\n* concurrent enrollment in conflicting research study\n* self-reported history of recurrent urinary tract-infections (≥2 urinary tract infections within 6 months or ≥3 within a year) and\u002For recurrent vaginal yeast infections (≥2 vaginal yeast infections within 6 months or ≥3 within a year)","FEMALE","45 Years","75 Years",{"count":163,"type":19},80,[165],"PHASE2","Women with HIV have an increased risk of having a myocardial infarction (heart attack) as compared to women without HIV. One of the mechanisms underlying the increased risk of myocardial infarction among women with HIV may involve reduced ability to increase blood flow through large and small coronary arteries at times when increased flow of oxygen-carrying blood is needed. We are conducting a study randomizing women with HIV and either diabetes, chronic kidney disease, or both to health education alone or to health education plus referral to see either an Endocrinologist or a Nephrologist in a subspecialty clinic for consideration of treatment with medication in a class known as sodium glucose transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors are clinically approved for use in patients with diabetes or chronic kidney disease but have been shown to be underutilized in people with HIV. One of our key analytic aims will be to test if SGLT2 inhibitor therapy results in improved blood flow through the large and small coronary arteries among women with HIV and either diabetes, chronic kidney disease, or both but who have no history of myocardial infarction. A second aim will be to test if subspecialty clinic referral (with or without SGLT2 inhibitor therapy prescription) results in improved blood flow through the large and small coronary arteries among the same group.",[168,26,169],"HIV-1-infection","Metabolic Disease",[171,172,173,174,175,176,177],"HIV","women","diabetes","chronic kidney disease","SGLT2 inhibitor therapy","coronary flow reserve","cardiovascular disease prevention","2025-10-14",{"date":180,"type":38},"2025-10-15",{"date":182,"type":38},"2025-04-17",{"date":184,"type":19},"2029-06",{"name":186,"class":45},"Massachusetts General Hospital",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":20,"phases":196,"briefSummary":198,"conditions":199,"keywords":200,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":46},"100514902","phase-4-a-study-on-the-impact-of-bivalirudin-usage-during-pci-for-high-risk-plaques-on-post-pci-coronary-microcirculation-100514902","NCT05984537","A Study on the Impact of Bivalirudin Usage During PCI for High-risk Plaques on Post-PCI Coronary Microcirculation.","A Study on the Impact of Bivalirudin Usage During Percutaneous Coronary Intervention for High-risk Plaques in the Coronary Artery on Post Percutaneous Coronary Intervention Coronary Microcirculation.","PCI","Inclusion Criteria:\n\n1. aged 18 years or older;\n2. diagnosed with non-ST-segment elevation myocardial infarction or unstable angina pectoris;\n3. scheduled to undergo elective coronary angiography and intervention;\n4. coronary computed tomography angiography showing high-risk plaque features within 3 months prior to the procedure;\n5. voluntary participation in the study and signed informed consent.\n\nExclusion Criteria:\n\n1. prior PCI of the target vessel within 3 months;\n2. cardiogenic shock, active bleeding, bleeding disorders, irreversible coagulation dysfunction, severe liver dysfunction (Child-Pugh class C), severe renal dysfunction (eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m2), and dependence on dialysis;\n3. life expectancy less than 1 year;\n4. chronic total occlusion of the target vessel;\n5. poor opacification of the target vessel, severe vessel overlap or distortion, and inability to completely expose the lesion site;\n6. allergy to contrast agents, verapamil, or its excipients;\n7. severe uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg);\n8. subacute bacterial endocarditis.",{"count":113,"type":19},[197],"PHASE4","In this study, investigators enrolled patients with coronary heart disease who were scheduled to undergo percutaneous coronary intervention (PCI) and had high-risk plaques according to computed tomography angiography (CTA). During the PCI procedure, patients will be randomly assigned to receive either bivalirudin or standard heparin anticoagulation therapy. Investigators will compare the post-PCI coronary angiography-derived index of microcirculatory resistance (CaIMR), thrombolysis in myocardial infarction (TIMI) blood flow grade, CTFC (corrected TIMI frame count), TIMI myocardial perfusion grading(TMPG), levels of troponin, and major adverse cardiac events (MACE) during a follow-up period of 6 months between the two groups. Investigators aim to explore the potential benefits of bivalirudin perioperative anticoagulation therapy in improving coronary microvascular dysfunction (CMD) after PCI for high-risk plaques in coronary artery lesions.",[26],[201,202,203,204,205],"coronary microvascular dysfunction","computed tomography angiography","percutaneous coronary intervention","bivalirudin","heparin","2025-08-07",{"date":208,"type":38},"2025-08-12",{"date":210,"type":38},"2023-07-01",{"date":212,"type":19},"2026-01-04",{"name":214,"class":45},"Peking University First Hospital",{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":224,"conditions":225,"keywords":227,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":46},"100577187","assessment-of-coronary-microvascular-dysfunction-after-stemi-using-continuous-saline-thermodilution-100577187","NCT06795035","Assessment of Coronary Microvascular Dysfunction After STEMI Using Continuous Saline Thermodilution","ConMicro STEMI: Assessment of Coronary Microvascular Dysfunction After ST-Elevation Myocardial Infarction Using Continuous Saline Thermodilution","ConMICRO STEMI","Inclusion Criteria:\n\n* Adults (persons \\>18 years old) presenting to Cleveland Clinic cardiac catheterization lab within 24 hours of symptom onset, with clinical and EKG findings concerning for STEMI, with intent to undergo emergent primary PCI, who have culprit artery identified on diagnostic angiography\n* Adults (persons \\>18 years old) presenting to Cleveland Clinic cardiac catheterization lab for pharmaco-invasive management of failed fibrinolysis, with intent to undergo emergent PCI, who have culprit artery identified on diagnostic angiography\n* On-call treating interventional cardiologist is trained in the method of continuous saline thermodilution for coronary microvascular assessment\n\nExclusion Criteria:\n\n* No evidence of coronary obstruction on diagnostic angiography (e.g., Takotsubo, myocarditis leading to STEMI activation).\n* Patients in hemodynamic shock\n* Culprit artery \\\u003C3.0 mm in diameter.\n* Culprit artery being a bypass graft\n* Patients physically unable to tolerate additional time required to conduct coronary microvascular testing after primary PCI.\n* Patients with eGFR \\\u003C30 mL\u002Fmin\u002F1.73m2 are excluded from contributing cardiac MRI data\n* Patients with standard contraindications to CMR (e.g., pacemakers, cochlear implants, certain prosthetic heart valves, certain surgical implants) are excluded from contributing cardiac MRI data\n* Unable to provide verbal and written consent\n* Pregnancy",{"count":113,"type":19},"The goal of this observational study to measure the heart's microvascular function in the setting of a myocardial infarction (MI), or heart attack, using a method called continuous saline thermodilution (CST). The participants will include people who are experiencing MI from sudden and complete blockage of a coronary artery requiring immediate balloon and\u002For stent therapy. After getting the balloon and\u002For stent therapy, participants will have their heart's microvascular system tested using CST. The main questions it aims to answer are:\n\n* What measurements using CST can we expect from the heart's microvascular system during a treated MI?\n* Can CST measurements during a treated MI predict the amount of heart muscle that is injured and that recovers?\n\nFor this study, participants will undergo measurement of their heart's microvascular function after balloon and\u002For stent therapy for the MI. They will then receive an MRI scan of the heart several days after the MI.",[25,26,226],"Microvascular Obstruction",[228,229,230,231,232],"STEMI","Microvascular","MVO","MRR","Thermodilution","2025-07-29",{"date":235,"type":38},"2025-07-31",{"date":237,"type":38},"2025-05-29",{"date":239,"type":19},"2027-12-31",{"name":241,"class":45},"The Cleveland Clinic",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":251,"conditions":252,"keywords":254,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":268},"100353003","womens-ischemia-syndrome-evaluation-wise-pre-hfpef-100353003","NCT03876223","Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF","Women's Ischemia Syndrome Evaluation (WISE) Mechanisms of Coronary Microvascular Dysfunction Leading to Pre-Heart Failure With Preserved Ejection Fraction (HFpEF)","Inclusion:\n\n1. 180 symptomatic men and women undergoing invasive coronary angiography for suspected ischemia with no obstructive CAD, defined as ≥50% luminal diameter stenosis in ≥1 epicardial coronary artery.\n2. Preserved left ventricular ejection fraction (EF) ≥45%\n3. Be \\> 18 years old\n4. Be able to meet the requirement for a cardiac MRI, which means no metal devices in your chest, no claustrophobia and no angioedema\n5. Be competent to give informed consent\n\nExclusion:\n\n1. Subjects with severe or chronic kidney disease (CKD) with GFR\\\u003C405 or acute kidney injury\n2. Subjects with allergy to animal dander will be excluded since imaging will be done in BIRI (BIRI scanners are also used to image animals).\n3. Subjects who have had four or more prior previous gadolinium contrast scans\n4. Allergy\u002F hypersensitivity to adenosine, gadolinium, aminophylline or regadenoson\n5. Second- or third-degree A-V block\n6. Sinus node disease, such as sick sinus syndrome or symptomatic bradycardia (except in patients with a functioning artificial pacemaker)\n7. Subjects with mild to severe asthma",{"count":250,"type":19},180,"The purpose of this study is to examine small vessel disease (a condition in which the small arteries in the heart become narrowed). The investigators want to know how the small vessel disease contributes to pre-HFpEF (a condition with inadequate heart muscle function in the setting of preserved muscle pumping) and to better identify potential treatment for prevention of HFpEF. The main procedures of this study include up to 2 clinic visits (initial visit and a second clinical visit only if participants are unable to complete all research procedures at the initial visit); a 6-week phone interview visit, 4 quarterly follow-up phone interview visits in year 1; year 1 follow up cardiac MRI based on availability and ongoing annual follow-up phone interview visits to track progress. If participants choose to take part in this study, participants direct participation will end after 1 year, participants will then have the option of participating in ongoing annual check-in calls. Participants will be asked to undergo a physical exam and provide a completed medical history; complete a Cardiovascular (or Cardiac) Magnetic Resonance Imaging (CMRI) with contrast agent; complete questionnaires to describe heart symptoms and overall quality of life status; undergo blood draws to provide blood samples for research testing, and allow the study team to have access to medical records.",[26,253],"Heart Failure With Preserved Ejection Fraction (HFpEF)",[255,256,257,258],"Coronary Microvascular Dysfunction (CMD)","Coronary Vascular Dysfunction (CVD)","Coronary angiography","Magnetic resonance imaging (MRI)","2025-06-27",{"date":261,"type":38},"2025-07-01",{"date":263,"type":38},"2019-07-24",{"date":265,"type":19},"2026-02-28",{"name":267,"class":45},"Cedars-Sinai Medical Center",2,{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":274,"acronym":275,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":277,"targetDuration":4,"studyType":20,"phases":279,"briefSummary":280,"conditions":281,"keywords":286,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":70},"100562719","phase-4-the-effects-of-tirzepatide-in-people-with-overweightobesity-and-coronary-artery-disease-100562719","NCT06606821","The Effects of Tirzepatide in People With Overweight\u002FObesity and Coronary Artery Disease","The Effects of Tirzepatide on Coronary Plaque Lipid Content and Myocardial Microvascular Function in Overweight and Obese People With Coronary Disease - The IDEAL-COR Study","IDEAL-COR","Inclusion Criteria:\n\n* Informed written consent\n* BMI equal to or above 27 kg\u002Fm2\n* Age 18 years or older\n* Referred to coronary angiogram (CAG) due to stable angina\n* Coronary atheromatosis by angiography (obstructive or non-obstructive)\n* LCBI4mm \\>200 by NIRS in a vessel not subjected to coronary intervention\n\nExclusion Criteria:\n\n* History of diabetes or HbA1c ≥48 mmol\u002Fmol (6.5%) at baseline\n* Treatment with Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA)\n* History of coronary artery bypass surgery (CABG)\n* Planned CV intervention (including percutaneous coronary intervention, cardiac surgery or transcatheter valve intervention) at time of randomisation\n* History of heart failure New York Heart Association (NYHA) class III or IV\n* Left ventricular ejection fraction (LVEF) ≤35%\n* eGFR \\\u003C30 ml\u002Fmin\u002F1.53 m2\n* History of pancreatitis or plasma amylase \\>2 times upper normal limit\n* Impaired hepatic function at baseline (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\>3 times the upper limit of normal)\n* Pregnancy, planned pregnancy or breastfeeding\n* Family or history of multiple endocrine neoplasia (MEN) type 2 or familial medullary thyroid carcinoma (FMTC)\n* Hypersensitivity to the active substance (Tirzepatide) or to any of the excipients\n* Left main stenosis (≥50% diameter or haemodynamically significant)\n* Chronic total occlusion of any major coronary vessel\n* Multi-vessel disease or complex anatomy potentially requiring coronary bypass surgery\n* Coronary anatomy or pathology precluding the safe performance of intravascular imaging in all major coronary arteries not subjected to intervention",{"count":278,"type":19},124,[197],"The objective of this study is to investigate, as a proof-of-principle, long-term (52 weeks) effects of tirzepatide once-weekly vs. placebo on changes in coronary plaque composition and progression (assessed by NIRS), plaque burden (assessed by IVUS) and microvascular function (assessed by invasively measured CFR) in overweight and obese individuals with stable coronary artery disease (CAD). In addition, the objective of a baseline cross-sectional sub-study is to explore potential metabolic and cardiovascular (CV) predictors for high arteriosclerotic plaque burden in overweight and obese individuals and to establish a cohort for future research projects.",[117,26,282,283,284,285],"Overweight or Obesity","Stable Angina Pectoris","Chronic Coronary Artery Disease","Atherosclerosis Cardiovascular Disease",[287,288,289,290,291,283],"NIRS","IVUS","GLP-1","Tirzepatide","Intravascular imagining","2025-05-19",{"date":294,"type":38},"2025-05-22",{"date":296,"type":38},"2024-10-01",{"date":298,"type":19},"2028-08-01",{"name":300,"class":45},"Tina Vilsbøll",{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":20,"phases":310,"briefSummary":311,"conditions":312,"keywords":314,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":46},"100562029","insulin-resistance-and-coronary-microvascular-dysfunction-in-patients-with-myocardial-ischemia-and-non-obstructive-coronary-artery-disease-100562029","NCT06597851","Insulin Resistance and Coronary Microvascular Dysfunction in Patients with Myocardial Ischemia and Non-obstructive Coronary Artery Disease","IRIN","Inclusion Criteria:\n\n* Aged over 18 years.\n* Cardiac chest pain with evidence of myocardial ischemia at noninvasive myocardial stress imaging and clinical indication to diagnostic coronary angiography\n* Willing and able to give informed consent for participation in the study\n\nExclusion Criteria:\n\n* Obstructive CAD (defined as more than 70% luminal stenosis and\u002For FFR ≤0.80 in 1 or more epicardial vessels).\n* History of previous myocardial infarction, percutaneous revascularization or coronary-aortic bypass graft (CABG) surgery.\n* Diagnosis of type II diabetes.\n* BMI ≥ 35 kg\u002Fm2.\n* Stage IV and V of chronic kidney disease (eGFR ≤ 30 ml\u002Fmin, estimated through CKD - EPI Creatinine Equation).\n* Allergy or other contraindication to iodinated contrast and\u002For gadolinium and\u002For adenosine.\n* Chronic resting O2 saturation ≤ 85%.\n* Pregnancy or suspected pregnancy.",{"count":309,"type":19},40,[22],"The goal of this prospective study is to assess the correlation between coronary microvascular disfunction and insulin resistance in patients with INOCA.\n\nPatients with ANOCA and without diabetes will undergo invasive coronary microvascular assessment through coronary angiography and insulin resistance assessment through hyperinsulinemic-euglycemic clamp test.\n\nPatients enrolled in the study will be followed for a period of 2 years to monitor their clinical status.",[26,58,313],"Insulin Resistance",[26,58,313,315,316,317,318],"INOCA","ANOCA","CMD","hyperinsulinemic-euglycemic clamp test","2024-09-12",{"date":321,"type":38},"2024-09-19",{"date":323,"type":38},"2024-06-24",{"date":325,"type":19},"2026-06-30",{"name":327,"class":45},"Azienda Ospedaliera Universitaria Integrata Verona",{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":336,"sex":15,"minAge":337,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":347,"leadSponsor":349,"locationsCount":46},"100556803","mechanisms-behind-microvascular-dysfunction-in-inoca-100556803","NCT06529861","Mechanisms Behind Microvascular Dysfunction in INOCA","Identification of Mechanisms Behind Microvascular Dysfunction in Ischemia With No Obstructive Coronary Artery Disease","ExINOCA-P1","Inclusion Criteria:\n\nOnly for angina patients: Have CMD, defined as myocardial bloodflow re-serve (MBFR) \\\u003C 2.5 or hyperemic myocardial blood flow (hMBF) \\\u003C 2.3ml\u002Fg\u002Fmin\n\nExclusion Criteria:\n\n* Females of childbearing potential (defined as a premeno-pausal female capable of becoming pregnant). The female patient must either be postmenopausal, defined as amen-orrhea for at least 1 year, or surgically sterile\n* Heart failure, defined as left ventricular ejection fraction of less than 40%\n* Uncontrolled hypertension defined as blood pressure above target 140\u002F90 for all\n* Co-morbidity resulting in \\\u003C1 year expected survival\n* Considered by the investigator, for any reason, to be an unsuitable candidate for the study.\n* Unable or unwilling to exercise, e.g. due to arthritis or injury\\*\n* Already are regularly physically active and\u002For have a maximal oxygen uptake \\>45 ml\u002Fkg\u002Fmin\n* The subject has a known allergy to either: norepinephrine, adenosine, ketorolac, and or ascorbic acid (vitamin C).",true,"50 Years",{"count":339,"type":19},60,"The purpose of the study is to identify the causes of chest pain in patients experiencing chest pain with no signs of narrowing in the coronary arteries of the heart.",[26,342],"Ischaemia With Non Obstructed Coronary Arteries","2024-07-29",{"date":345,"type":38},"2024-07-31",{"date":296,"type":19},{"date":348,"type":19},"2028-05-15",{"name":350,"class":45},"Bispebjerg Hospital",{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":359,"conditions":360,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":367,"leadSponsor":369,"locationsCount":46},"100554788","coronary-microvascular-dysfunction-in-angina-patients-with-non-obstructive-coronary-artery-disease-anoca-cmd-100554788","NCT06503640","Coronary Microvascular Dysfunction in Angina Patients With Non-obstructive Coronary Artery Disease (ANOCA-CMD)","Coronary Microvascular Dysfunction in Angina Patients With Non-obstructive Coronary Artery Disease","Inclusion Criteria:\n\n* presence of stable anginal symptoms, a clinical indication for invasive coronary angiography, and no hemodynamically significant epicardial coronary artery disease, defined as fractional flow reserve (FFR) \\>0.80\n\nExclusion Criteria:\n\n1. acute myocardial infarction\n2. significant valvular heart disease\n3. advanced chronic kidney disease\n4. patients with significant epicardial coronary artery stenosis (\\>70% in major vessels by diagnostic coronary angiography) needing percutaneous coronary intervention\n5. patients unable to provide written informed consent",{"count":18,"type":19},"The goal of this observational study is to explore the incidence and effect on prognosis of coronary microvascular dysfunction in patients present of stable anginal symptoms, a clinical indication for invasive coronary angiography, and no hemodynamically significant epicardial coronary artery disease, defined as fractional flow reserve (FFR) \\>0.80.",[361,26,362],"Angina Patients With Non-obstructive Coronary Artery Disease","Index of Microvascular Resistance","2024-07-10",{"date":365,"type":38},"2024-07-16",{"date":210,"type":38},{"date":368,"type":19},"2025-12-31",{"name":370,"class":45},"China-Japan Friendship Hospital",{"id":372,"slug":373,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":377,"targetDuration":4,"studyType":83,"phases":4,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":70},"100513054","coronary-microvascular-disease-cmd-registry-100513054","NCT05960474","Coronary Microvascular Disease (CMD) Registry","Inclusion Criteria:\n\n* Those with Coronary Microvascular Disease",{"count":378,"type":19},1000,"The purpose of this project is to provide appropriate administrative and technical supports for the warehousing and use of a database of patients with coronary microvascular disease (CMD). This protocol will outline the process for identification and capture of data, storage, as well as data use and sharing internally and externally for research purposes.",[26],"2024-06-06",{"date":383,"type":38},"2024-06-07",{"date":385,"type":38},"2023-02-01",{"date":387,"type":19},"2033-01",{"name":389,"class":45},"Medstar Health Research Institute",{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":394,"acronym":395,"eligibilityCriteria":396,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":397,"targetDuration":399,"studyType":83,"phases":4,"briefSummary":400,"conditions":401,"keywords":403,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":414},"100546326","southeastern-europe-microcirculation-registry-100546326","NCT06393478","Southeastern Europe Microcirculation Registry","SATURATION","Inclusion Criteria:\n\n* Adults of both sexes older than 18 years\n* Angina symptoms or angina equivalent\n* Referred to Cath lab for evaluation of CAD\n* Invasive physiology testing performed (microcirculation testing +\u002F- vasospasm testing) using Coroflow Coroventis Cardiovascular system (Abbott Vascular, Abbott Park, IL, USA)\n\nExclusion Criteria:\n\n* Persons under the age of 18\n* Pregnant of nursing\n* No coronary physiology measurements performed",{"count":398,"type":19},900,"5 Years","SATURATION is a prospective multicenter registry of consecutive patients who undergo coronary physiology testing using Pressure Wire X and Coroflow Coroventis Cardiovascular System software (Abbott Vascular, Abbott Park, IL, USA) and to assess the regional practice of patient selection, cardiovascular outcomes and additional procedures (stress testing, angiography, etc.) done after comprehensive invasive coronary physiology evaluation.",[402,26,117],"Angina, Microvascular",[404],"microvascular angina, thermodilution, coronary flow reserve","2024-05-12",{"date":407,"type":38},"2024-05-14",{"date":409,"type":38},"2024-03-01",{"date":411,"type":19},"2034-03-01",{"name":413,"class":45},"Institute for Cardiovascular Diseases Dedinje",10,{"id":416,"slug":417,"hasResults":11,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":423,"targetDuration":4,"studyType":20,"phases":425,"briefSummary":426,"conditions":427,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":46},"100545033","study-of-microvascular-dysfunction-cfr-and-cardioprotective-effect-of-early-administration-of-esmolol-in-mi-100545033","NCT06376630","Study of Microvascular Dysfunction, CFR and Cardioprotective Effect of Early Administration of Esmolol in MI","Study of Microvascular Dysfunction, Coronary Flow Reserve and Cardioprotective Effect of Early Intravenously Administration of Esmolol in Patients With Myocardial Infarction","ESMO-VASCMI","Substudy evaluating cardioprotective effects of early iv administration of esmolol\n\nInclusion Criteria:\n\n* Diagnosed acute ST elevation MI, type 1, within the first 8 hours of disease onset;\n* Treating physician's decision not to administer metoprolol intravenously prior to primary PCI due to a high risk of complications (BP \\\u003C 120\u002F80 mm Hg at baseline examination, moderate evidence of heart failure (Killip 2) or a risk of its development (LV EF ≤ 30%), first degree AV block with PQ ≥ 0.25 ms, history of asthma or severe COPD etc.)\n* Signed Informed Consent to participate in the study\n\nExclusion Criteria:\n\n* severe heart failure (pulmonary edema; SCAI В-Е cardiogenic shock);\n* atrioventricular conduction abnormality higher than first degree, without a pacemaker;\n* sinus bradycardia with the heart rate of \\\u003C 60 bpm;\n* BP \\\u003C 100\u002F60 mm Hg.;\n* asthma in exacerbation;\n* history of a STEMI in the IRA basin;\n* clinically significant bleeding or hypovolemia;\n* hypersensitivity to esmolol;\n* pregnancy or lactation;\n* known severe comorbidities independently affecting prognosis (Child Pugh class C liver failure, active malignancies etc.);\n* contraindications to MRI (MR-incompatible pacemaker\u002Fimplanted cardioverter-defibrillator, cochlear implants, clips on brain vessels, foreign metal objects - bullets, intraorbital metal fragments, insulin pumps, body weight above 150 kg, history of allergies to gadolinium, claustrophobia);\n* severe dementia;\n* known severe comorbidities independently affecting prognosis (chronic renal or liver failure, active malignancies etc.);\n* complicated PCI, \"no reflow\" phenomenon on follow-up coronary angiography;\n* thrombolysis for AMI;\n* ECG evidence of spontaneous reperfusion on admission;\n* patient's refusal from participation in the study.\n\nSubstudy investigating coronary physiology\n\nInclusion Criteria:\n\n* Diagnosed MI, completed PCI for the IRA and multivessel Coronary Artery Disease with diameter stenosis of 50-85% in non-IRA.\n* Signed Informed Consent to participate in the study\n\nExclusion criteria:\n\n* History of coronary artery bypass grafting surgery;\n* Non-IRA lesions resulting in diameter stenosis of below 50% and above 85%, main left coronary artery (LCA) stenosis above 50%;\n* Chronic kidney disease stage 3b or above (glomerular filtration rate below 45 mL\u002Fmin\u002Fm2 according to the CKD-EPI equation);\n* History of a contrast-induced nephropathy (CIN) or a high CIN risk (calculated using the Mehran score);\n* History of allergies to iodine-containing medications;\n* Pregnancy or lactation;\n* Left ventricle ejection fraction ≤ 30%;\n* Known severe comorbidities independently affecting prognosis (chronic renal or liver failure, active malignancies etc.);\n* Early post-infarction angina;\n* Severe dementia;\n* Patient's refusal from participation in the study.",{"count":424,"type":19},300,[22],"Study rationale: to evaluate clinical and prognostic relevance of microvascular dysfunction, coronary flow reserve and cardioprotective effects of iv administration of esmolol in patients with myocardial infarction.\n\nFirst substudy is an open randomized trial evaluating the efficacy and safety of early intravenous administration of esmolol in patients with acute ST-segment elevation myocardial infarction (MI) and relative contraindications to administration of other intravenous β1-adrenergic blocker (metoprolol etс.). Сomparison group will include patients who have not received intravenous β1-adrenergic blocker. Secondary outcome in this substudy is the degree of microvascular obstruction and infarct size according to MRI with gadolinium delayed enhancement.\n\nSecond substudy examines the quantitative parameters of coronary physiology in patients with MI and multivessel disease. Changes of coronary physiology measurements over time ((iFR, Pd\u002FPa, FFR, delta FFR, gradient FFR per time unit (dFFR(t)\u002Fdt), pullback pressure gradient (PPG)) measured in the infarct-related artery and in non-infarct-related arteries with diameter stenosis of 50-85% immediately after the completion of a primary percutaneous coronary intervention and during a second hospitalization (30-45 days after STEMI) will be evaluated. The comparison changes of coronary physiology over time with presence of an MVO and infarct size determined by MRI. The model of calculating coronary flow reserve (CFR) based on tridimensional reconstruction of coronary arteries and coronary physiology parameters as measured during coronary angiography will be developed. The influence of coronary physiology parameters measured after complete myocardial revascularization by PCI, and derived CFR in patients with MI on long-term clinical outcomes will be evaluated, based on prospective data collection.\n\nPrimary composite outcome in all substudies will be the sum of adverse cardiac outcomes (congestive heart failure, episodes of recurrent congestive heart failure worsening resulting in hospitalizations, cardiac mortality, MI recurrences, unstable angina, urgent myocardial revascularization) within \\> 12 months post-infarction.\n\nSecondary composite outcome in all substudies is the degree of microvascular obstruction and infarct size evaluated by MRI with gadolinium delayed enhancement.",[86,428,26],"Coronary Stenosis","2024-04-18",{"date":431,"type":38},"2024-04-19",{"date":433,"type":38},"2024-01-29",{"date":435,"type":19},"2030-01-29",{"name":437,"class":438},"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","OTHER_GOV",{"id":440,"slug":441,"hasResults":11,"nctId":442,"briefTitle":443,"officialTitle":443,"acronym":444,"eligibilityCriteria":445,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":446,"enrollmentInfo":447,"targetDuration":4,"studyType":20,"phases":449,"briefSummary":450,"conditions":451,"keywords":454,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":4},"100515686","impact-of-renal-denervation-in-patients-with-coronary-microvascular-dysfunction-study-design-and-rationale-100515686","NCT05994729","Impact of Renal Denervation in Patients With Coronary Microvascular Dysfunction: Study Design and Rationale","IMPRESSION","Rul-in Phase Inclusion Criteria:\n\n* Non obstructive stable coronary artery disease (CAD) on invasive coronary angiography (defined as the absence of either \\>50% angiographic stenosis or any flow limiting lesion on functional evaluation)\n* Suspected diagnosis of difficult to control\u002F resistant hypertension for which renal denervation by radiofrequency ablation with Spyral Symplicity 3 could be considered.\n\nRule-in Phase Exclusion Criteria:\n\n* Initiation of either nitrates, beta-blocker or calcium channel blocker less than 30 days before the end of the rule-in phase\n* Physiological assessment performed during first medical contact documenting preserved coronary microvascular function\n* Physiological assessment performed at the \"first contact\" hospitalization followed by modification of medical therapy during the rule-in phase, before RDN\n* Acceptable blood pressure control after medical treatment optimization\n* Identification of secondary causes of hypertension\n* Renal artery anatomy not suitable for RDN\n* Ejection fraction below 30%\n* Life expectancy below 1 year\n* Indication to cardiac surgery\n* Adenosine allergy\n* Pregnancy\n* Large necrotic area documented by either MRI, SPECT or combination of ECG signs + Echocardiographic images.\n* Hemodynamic instability\n* Refuse to sign informed consent\n* Age below 18 or above 80\n\nStudy Phase Inclusion Criteria:\n\n* Having coronary microvascular dysfunction documented by invasive functional assessment (IMR\\>25 and or CFR \\\u003C 2)\n* Fulfilling all the rule-in phase inclusion criteria without any rule-in phase exclusion criteria\n\nStudy Phase Exclusion Criteria:\n\n* Refuse to sign informed consent\n* Evidence of newly detected obstructive CAD on invasive coronary angiography performed 6 months after RDN","80 Years",{"count":448,"type":19},87,[22],"Long-standing hypertension may cause an impairment in microvascular coronary circulation which is involved in many different cardiac conditions. Renal denervation (RDN) has been successfully proven as a valuable and powerful therapeutic choice to consider for patients with resistant hypertension; moreover this procedure looks promising in other cardiac disease such as heart failure and atrial fibrillation, given its ability to downregulate sympathetic nervous system The aim of this study is to explore the effect of renal denervation and blood pressure control on coronary microvascular dysfunction.\n\nThis is a multicenter, prospective, non randomized, open-label, interventional study. Consecutive patients with resistant hypertension, non obstructive coronary artery disease and documented microvascular dysfunction will be enrolled. Patients will undergo renal denervation by Spyral Symplicity 3 and re-assessment of coronary microvascular function 12 months after the procedure. Primary endpoint will be the difference in average index of microcirculatory resistance value.",[26,452,453],"Resistant Hypertension","Hypertensive Heart Disease",[455,456],"MVD","HHD","2023-10-22",{"date":459,"type":38},"2023-10-24",{"date":461,"type":19},"2024-01-01",{"date":463,"type":19},"2026-12-31",{"name":465,"class":45},"Aurelia Hospital",{"id":467,"slug":468,"hasResults":11,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":472,"eligibilityCriteria":473,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":474,"targetDuration":476,"studyType":83,"phases":4,"briefSummary":477,"conditions":478,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":480,"lastUpdatePostDateStruct":481,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":486,"locationsCount":488},"100522931","belgian-registry-on-coronary-function-testing-100522931","NCT06089031","Belgian Registry on Coronary Function Testing","A Prospective Multicenter Registry on Coronary Function Tests, Organized by the Belgian Working Group on Coronary Microcirculation\u002FBelgian Microcirculation Registry.","BELmicro","Inclusion Criteria:\n\n* Patient scheduled for coronary function test, comprising of intracoronary bolus thermodilution measurements of microvascular function, and\u002For intracoronary vasoreactivity tests with acetylcholine.\n* Subject understands the study requirements and provides written informed consent.\n\nExclusion Criteria:\n\n* Subject is participating in another investigational clinical trial that may cause non-compliance with the protocol or confound data interpretation.\n* Subject intends to participate in another investigational clinical trial that may cause non-compliance with the protocol or confound data interpretation.\n* Documented or suspected pregnancy.\n* Inability to provide written informed consent.",{"count":475,"type":19},650,"3 Years","The goal of this prospective, multicenter registy is to describe the 'real-world' use of coronary function tests, which may consist of bolus thermodilution measurements of coronary microvascular function and\u002For invasive vasoreactivity tests with acetylcholine, in the current Belgian routine practice. The main questions it aims to answer are:\n\n* how frequent are coronary function tests performed\n* what is the indication for coronary function tests\n* what is the frequency of coronary microvascular dysfunction\n* what is the frequency of coronary artery vasospasm\n\nFrom each participant, data will be collected from their medical files concerning cardiovascular risk factors, relevant past medical history, non-invasive tests, procedural data, and follow-up data from routine in-patient visits. Their are no specific study visits. Optionally, patients will be asked to fill in questionnaires about anginal symptoms and quality of life.",[26,479],"Coronary Artery Vasospasm","2023-10-12",{"date":482,"type":38},"2023-10-18",{"date":484,"type":38},"2021-10-18",{"date":463,"type":19},{"name":487,"class":45},"University Hospital, Antwerp",13]